Stockscreener 앱 받기
2.29
0.87%
-0.02
시간 외 거래:
2.29
전일 마감가:
$2.31
열려 있는:
$2.34
하루 거래량:
64,860
Relative Volume:
0.39
시가총액:
$47.76M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-0.3855
EPS:
-5.94
순현금흐름:
$-35.26M
1주 성능:
-11.24%
1개월 성능:
+13.93%
6개월 성능:
-21.84%
1년 성능:
+100.88%
1일 변동 폭
$2.28
$2.40
1주일 범위
$2.21
$2.60
52주 변동 폭
$1.04
$5.24
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TARA | 2.29 | 47.76M | 0 | -42.05M | -35.26M | -5.94 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
HC Wainwright Analysts Decrease Earnings Estimates for TARA - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 18.1% in October - MarketBeat
Protara Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Protara to Present Key TARA-002 Phase 2 Trial Data for Bladder Cancer Treatment | TARA Stock News - StockTitan
Woodline Partners LP Acquires Shares in Protara Therapeutics Inc - GuruFocus.com
HC Wainwright Reiterates "Buy" Rating for Protara Therapeutics (NASDAQ:TARA) - MarketBeat
Protara Therapeutics Reports Increased R&D Expenses - TipRanks
Protara Therapeutics: Q3 Earnings Snapshot - CT Insider
Protara Therapeutics reports Q3 EPS (50c), consensus (52c) - TipRanks
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Protara Therapeutics: FDA Fast Track Win, Strong Trial Progress Despite Wider Q3 Loss | TARA Stock News - StockTitan
Protara Therapeutics Inc (TARA) Quarterly 10-Q Report - Quartzy
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewswire
FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia
FDA fast tracks Protara's choline chloride therapy - Investing.com
Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance
Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India
Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada
Protara reveals high choline deficiency in PS patients - Investing.com India
Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire
Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily
Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex
A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News
Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart
Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily
Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com
TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World
Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World
Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):